CROI 2013: Pipeline Antiretrovirals Promise More Effective and Better Tolerated HIV Treatment
- Details
- Category: HIV Treatment
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
New antiretroviral drugs and treatment strategies are no longer the predominant focus of the annual Conference on Retroviruses and Opportunistic Infections (CROI), but this year's meeting included several presentations on refinements to HIV therapy that offer the prospect of greater efficacy -- especially for people with resistant virus -- fewer side effects, and more convenient administration.
- CR5/CCR2 Inhibitor Cenicriviroc Has Both Anti-HIV and Anti-inflammatory Effects
- New Antiretroviral Agents: Cenicriviroc [VIDEO]
- New Pro-drug Tenofovir Alafenamide Appears Equally Effective but Better Tolerated
- New Tenofovir Alafenamide Looks Easier on Kidneys [VIDEO]
- MK-1439, a Novel HIV NNRTI, Shows Promise in Early Clinical Trials
- Dolutegravir Helps Highly-resistant Treatment-experienced People on Failing ART
- Can People with Resistant HIV Omit NRTIs When Switching to a New Regimen? [VIDEO]